ProQR Therapeutics N.V. (PRQR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PRQR Profit Margin, ROE & Profitability Analysis
PRQR vs Healthcare Sector: How ProQR Therapeutics N.V. Compares
How ProQR Therapeutics N.V. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ProQR Therapeutics N.V. Stock Overvalued? PRQR Valuation Analysis 2026
Based on fundamental analysis, ProQR Therapeutics N.V. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ProQR Therapeutics N.V. Balance Sheet: PRQR Debt, Cash & Liquidity
PRQR Revenue Growth, EPS Growth & YoY Performance
PRQR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ProQR Therapeutics N.V. (CIK: 0001612940)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRQR
What is the AI rating for PRQR?
ProQR Therapeutics N.V. (PRQR) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRQR's key strengths?
Claude: Analysis in progress.
What are the risks of investing in PRQR?
Claude: Analysis in progress.
What is PRQR's revenue and growth?
ProQR Therapeutics N.V. reported revenue of N/A.
Does PRQR pay dividends?
ProQR Therapeutics N.V. does not currently pay dividends.
Where can I find PRQR SEC filings?
Official SEC filings for ProQR Therapeutics N.V. (CIK: 0001612940) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRQR's EPS?
ProQR Therapeutics N.V. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PRQR's fundamental grade?
Based on our AI fundamental analysis in July 2026, ProQR Therapeutics N.V. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PRQR stock overvalued or undervalued?
Valuation metrics for PRQR: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PRQR's AI grade for 2026?
Our dual AI analysis gives ProQR Therapeutics N.V. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PRQR's free cash flow?
ProQR Therapeutics N.V.'s operating cash flow is N/A, with capital expenditures of N/A.
How does PRQR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).